Cytek Biosciences, Inc. (CTKB) Misses Q4 EPS by 32c, provides guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q4 EPS of ($0.34), $0.32 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $62.1 million versus the consensus estimate of $57.14 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2026 revenue of $205-212 million, versus the consensus of $207.4 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters
• RH (RH) Tops Q1 EPS by 12c